Precision gene editing could prevent vision loss from Stargardt disease
Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, which often leads to vision loss. Their study shows promising results using a ...
Can gene editing help with hereditary eye diseases? A new study explores the possibility
Gene editing technique developed in Switzerland shows promise in curing Stargardt disease, a rare genetic eye disease causing ...
Benchmark sees growth for Belite Bio shares, highlights Tinlarebant's promise in rare diseases
Benchmark analysts have increased the price target for Belite Bio, Inc (NASDAQ:BLTE) shares to $79.00, up from the previous ...
GEN15d
Base Editing Addresses Inherited Macular Degeneration in Primate, Human Tissue Models
The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no ...
pharmaphorum1d
Alnylam scraps trial in rare eye disorder, blaming drug price reforms
Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...
Belite Bio (NASDAQ:BLTE) Shares Gap Up After Analyst Upgrade
Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) gapped up prior to trading on Wednesday after Benchmark raised their price ...
Belite Bio price target raised to $79 from $57 at Benchmark
Benchmark raised the firm’s price target on Belite Bio (BLTE) to $79 from $57 and keeps a Buy rating on the shares. After speaking to ...